Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 6, 2026
Lisata Therapeutics, Inc. (LSTA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $2.9 million. Free cash flow was -$2.6 million.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-2.93M
+37.1% vs year-ago quarter
Operating cash flow
$-2.65M
+33.0% vs year-ago quarter
Free cash flow
$-2.65M
+33.0% vs year-ago quarter
EPS
$-0.32
+40.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
9.01M
+2.9% vs year-ago quarter
Net cash
$27.60M
Q4 FY2024
Operating margin
-6954.3%
Q2 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LSTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Basking Ridge, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 320017
- Former names
- Caladrius Biosciences, Inc. (until Sep 15, 2022); CALADRIUS BIOSCIENCES, INC. (until Sep 15, 2022); NeoStem, Inc. (until Jun 5, 2015); PHASE III MEDICAL INC/DE (until Sep 1, 2006); CORNICHE GROUP INC /DE (until Aug 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $70,000 | $0 |
| Operating income | -$4.0M | -$4.9M | -$4.4M | -$4.9M | -$5.8M |
| Net income | -$2.9M | -$4.5M | -$4.2M | -$4.7M | -$4.7M |
| Diluted EPS | -$0.32 | -$0.50 | -$0.49 | -$0.54 | -$0.55 |
| Operating cash flow | -$2.6M | -$3.1M | -$3.3M | -$4.0M | -$5.4M |
| Free cash flow | -$2.6M | -$3.1M | -$3.3M | -$4.0M | -$5.4M |
| Total assets | $11.0M | $14.1M | $21.8M | $25.2M | $29.0M |
| Total liabilities | $3.0M | $3.4M | $4.6M | $4.4M | $3.9M |
| Stockholders' equity | $8.2M | $10.9M | $17.4M | $21.0M | $25.4M |
| Cash and investments | $19.3M | $21.8M | $33.5M | $34.1M | $43.2M |
| Total debt | — | — | $0 | $47,000 | $92,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 19, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 17, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Agreement ended, Other events
|
Jul 24, 2026 | Jul 24, 2026 |
All 1001 Lisata Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.